A Gene Signature for Predicting Outcome in Patients with Basal-like Breast Cancer

Overview

Journal Sci Rep

Specialty Science

Date 2012 Feb 23

PMID 22355741

Citations 56

Authors

Robin M Hallett

Anna Dvorkin-Gheva

Anita Bane

John A Hassell

Affiliations

Soon will be listed here.

Citing Articles

Cancer-Derived Extracellular Vesicle ITGB2 Promotes the Progression of Triple-Negative Breast Cancer via the Activation of Cancer-Associated Fibroblasts.

Fan J, Sha T, Ma B Glob Chall. 2025; 9(3):2400235.

PMID: 40071217 PMC: 11891567. DOI: 10.1002/gch2.202400235.

Molecular profiling of breast cancer methylation pattern in triple negative versus non- triple negative breast cancer.

Mohanad M, Hamza H, Bahnassy A, Shaarawy S, Ahmed O, El-Mezayen H Sci Rep. 2025; 15(1):6894.

PMID: 40011499 PMC: 11865568. DOI: 10.1038/s41598-025-90150-9.

The association between sarcopenia and clinical outcomes among Chinese patients with triple-negative breast cancer: a retrospective study.

Gu H, Zhu T, Ding J, Yang Z, Lu Y, Guo G Front Oncol. 2025; 15:1402300.

PMID: 39980560 PMC: 11839753. DOI: 10.3389/fonc.2025.1402300.

The potential benefits of radiotherapy in elderly patients with early-stage triple-negative breast cancer.

Xu Z, Qin C, Cao B, Ruan P, Zhang M, Chen G Front Med (Lausanne). 2025; 11():1525425.

PMID: 39845821 PMC: 11751052. DOI: 10.3389/fmed.2024.1525425.

Sterile Alpha Motif Domain-Containing 5 Suppresses Malignant Phenotypes and Tumor Growth in Breast Cancer: Regulation of Polo-Like Kinase 1 and c-Myc Signaling in a Xenograft Model.

Tuo Y, Ye Y Cureus. 2024; 16(11):e73259.

PMID: 39524172 PMC: 11550111. DOI: 10.7759/cureus.73259.

References

. 1997 update of recommendations for the use of tumor markers in breast and colorectal cancer. Adopted on November 7, 1997 by the American Society of Clinical Oncology. J Clin Oncol. 1998; 16(2):793-5. DOI: 10.1200/JCO.1998.16.2.793. View

Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M . A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004; 351(27):2817-26. DOI: 10.1056/NEJMoa041588. View

Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, Smeds J . Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst. 2006; 98(4):262-72. DOI: 10.1093/jnci/djj052. View

Blows F, Driver K, Schmidt M, Broeks A, van Leeuwen F, Wesseling J . Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. PLoS Med. 2010; 7(5):e1000279. PMC: 2876119. DOI: 10.1371/journal.pmed.1000279. View

Xie Y, Wolff D, Wei T, Wang B, Deng C, Kirui J . Breast cancer migration and invasion depend on proteasome degradation of regulator of G-protein signaling 4. Cancer Res. 2009; 69(14):5743-51. PMC: 2741027. DOI: 10.1158/0008-5472.CAN-08-3564. View

West M, Blanchette C, Dressman H, Huang E, Ishida S, Spang R . Predicting the clinical status of human breast cancer by using gene expression profiles. Proc Natl Acad Sci U S A. 2001; 98(20):11462-7. PMC: 58752. DOI: 10.1073/pnas.201162998. View

Nagahata T, Onda M, Emi M, Nagai H, Tsumagari K, Fujimoto T . Expression profiling to predict postoperative prognosis for estrogen receptor-negative breast cancers by analysis of 25,344 genes on a cDNA microarray. Cancer Sci. 2004; 95(3):218-25. PMC: 11160046. DOI: 10.1111/j.1349-7006.2004.tb02206.x. View

Haibe-Kains B, Desmedt C, Sotiriou C, Bontempi G . A comparative study of survival models for breast cancer prognostication based on microarray data: does a single gene beat them all?. Bioinformatics. 2008; 24(19):2200-8. PMC: 2553442. DOI: 10.1093/bioinformatics/btn374. View

Teschendorff A, Miremadi A, Pinder S, Ellis I, Caldas C . An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer. Genome Biol. 2007; 8(8):R157. PMC: 2374988. DOI: 10.1186/gb-2007-8-8-r157. View

10.

Ridolfi R, Rosen P, Port A, Kinne D, Mike V . Medullary carcinoma of the breast: a clinicopathologic study with 10 year follow-up. Cancer. 1977; 40(4):1365-85. DOI: 10.1002/1097-0142(197710)40:4<1365::aid-cncr2820400402>3.0.co;2-n. View

11.

Hayes D, Trock B, Harris A . Assessing the clinical impact of prognostic factors: when is "statistically significant" clinically useful?. Breast Cancer Res Treat. 1999; 52(1-3):305-19. DOI: 10.1023/a:1006197805041. View

12.

Johnson W, Li C, Rabinovic A . Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics. 2006; 8(1):118-27. DOI: 10.1093/biostatistics/kxj037. View

13.

Kreike B, Van Kouwenhove M, Horlings H, Weigelt B, Peterse H, Bartelink H . Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. Breast Cancer Res. 2007; 9(5):R65. PMC: 2242660. DOI: 10.1186/bcr1771. View

14.

Desmedt C, Haibe-Kains B, Wirapati P, Buyse M, Larsimont D, Bontempi G . Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin Cancer Res. 2008; 14(16):5158-65. DOI: 10.1158/1078-0432.CCR-07-4756. View

15.

Chang H, Nuyten D, Sneddon J, Hastie T, Tibshirani R, Sorlie T . Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc Natl Acad Sci U S A. 2005; 102(10):3738-43. PMC: 548329. DOI: 10.1073/pnas.0409462102. View

16.

Sorlie T, Tibshirani R, Parker J, Hastie T, Marron J, Nobel A . Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A. 2003; 100(14):8418-23. PMC: 166244. DOI: 10.1073/pnas.0932692100. View

17.

J van t Veer L, Dai H, van de Vijver M, He Y, Hart A, Mao M . Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002; 415(6871):530-6. DOI: 10.1038/415530a. View

18.

Van Troys M, Huyck L, Leyman S, Dhaese S, Vandekerkhove J, Ampe C . Ins and outs of ADF/cofilin activity and regulation. Eur J Cell Biol. 2008; 87(8-9):649-67. DOI: 10.1016/j.ejcb.2008.04.001. View

19.

Orlowski R, Kuhn D . Proteasome inhibitors in cancer therapy: lessons from the first decade. Clin Cancer Res. 2008; 14(6):1649-57. DOI: 10.1158/1078-0432.CCR-07-2218. View

20.

Paik S, Tang G, Shak S, Kim C, Baker J, Kim W . Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol. 2006; 24(23):3726-34. DOI: 10.1200/JCO.2005.04.7985. View